UCB, a global biopharmaceutical company, has announced a strategic divestment of its mature neurology and allergy business in China to CBC Group and Mubadala, a healthcare-focused asset management group and Abu Dhabi-based investment company, respectively. The transaction is valued at $680 million.   This move aligns with UCB’s strategy to shift its focus toward innovation and partnerships in the rapidly growing Chinese pharmaceutical market. The divested portfolio includes established brands ...